PE-22-28
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
PE-22-28 is a synthetic analog of spadin, an endogenous peptide that blocks the TREK-1 potassium channel. TREK-1 blockade is a well-known target for rapid-acting antidepressant research — TREK-1 knockout animals show a depression-resistant phenotype, which is what makes spadin and its analogs interesting.
What does it do in my body?
PE-22-28 is designed to modulate (inhibit) TREK-1 channels, the mechanism associated with rapid antidepressant-like effects in preclinical models. It’s labeled a spadin-derived peptide, TREK-1 inhibitor, with the appeal being speed — a different and faster pathway than classic monoamine antidepressants (SSRIs and similar).
How can it help me?
- Where the science stands: Preclinical/animal only; 0 studies cited, 0 human trials in the captured directory profile
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
Not documented. No human trials exist in the record this KB draws from, so there is no human side-effect profile to report.
Regulatory status: Research compound — not approved for human use. Tier D / encyclopedia-only. A scientifically clean mechanism (rapid antidepressant via TREK-1) with an entirely preclinical evidence base.
Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
None to give honestly. There is no human dosing data and no captured preclinical dosing detail in the source material — this is a mechanism-level research interest, not a compound with a real-world protocol.
What should I avoid combining — and what's synergistic?
PE-22-28 doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
A synthetic spadin analog aimed at rapid-acting antidepressant effects via TREK-1 channel blockade — a scientifically clean mechanism with an entirely preclinical evidence base and no human data.
| Class | Synthetic analog of spadin, an endogenous TREK-1 potassium channel blocker |
| Mechanism (one line) | Modulates (inhibits) TREK-1 potassium channels, a target associated with rapid antidepressant-like effects |
| Evidence base | Preclinical/animal only; 0 studies cited, 0 human trials in the captured directory profile |
| Safety record | No human safety data captured |
| Regulatory status | Research compound; not approved for human use |
What it is
PE-22-28 is a synthetic analog of spadin, an endogenous peptide that blocks the TREK-1 potassium channel. TREK-1 blockade is a well-known target for rapid-acting antidepressant research — TREK-1 knockout animals show a depression-resistant phenotype, which is what makes spadin and its analogs interesting.
How it works
PE-22-28 is designed to modulate (inhibit) TREK-1 channels, the mechanism associated with rapid antidepressant-like effects in preclinical models. It’s labeled a spadin-derived peptide, TREK-1 inhibitor, with the appeal being speed — a different and faster pathway than classic monoamine antidepressants (SSRIs and similar).
What the research shows
The directory profile this article draws from grades PE-22-28 anecdotal: 0 studies cited, 0 human trials and states no published clinical studies were found on PubMed. The 0035 deep-research categorization pass grades it Tier D: preclinical antidepressant data, no human trials — the spadin/TREK-1 preclinical antidepressant papers exist in the broader literature but are not attached in the captured profile, so the specific studies behind the claim are not yet pinned to citations here.
Real-world protocol
None to give honestly. There is no human dosing data and no captured preclinical dosing detail in the source material — this is a mechanism-level research interest, not a compound with a real-world protocol.
Side effects & management
Not documented. No human trials exist in the record this KB draws from, so there is no human side-effect profile to report.
Regulatory status
Research compound — not approved for human use. Tier D / encyclopedia-only. A scientifically clean mechanism (rapid antidepressant via TREK-1) with an entirely preclinical evidence base.
Sources
- (thepeptidelist.com directory capture, 2026-06-07)
- Tier D grading, spadin-derived / TREK-1 inhibitor description
- Migrated from
frontier-investigational-peptides-cluster.md(Section 1)
Sources & references
- (thepeptidelist.com directory capture, 2026-06-07)
- Tier D grading, spadin-derived / TREK-1 inhibitor description
- Migrated from
frontier-investigational-peptides-cluster.md(Section 1)